Brief: Gyre Therapeutics Announces China’S Nmpa Grants Priority Review To The NDA For Hydronidone (F351) For Chb-Induced Liver Fibrosis Treatment
17/03/2026 11:51
March 17 (Reuters) - Gyre Therapeutics Inc GYRE.O: GYRE THERAPEUTICS ANNOUNCES CHINA’S NMPA GRANTS PRIORITY REVIEW TO THE NDA FOR HYDRONIDONE (F351) FOR CHB-INDUCED LIVER FIBROSIS TREATMENT GYRE THERAPEUTICS INC - CO THROUGH UNIT PANS FORMAL NDA SUBMISSION FOR HYDRONIDONE IN NEAR FUTURE Source text: ID:nGNX1ptScX Further company coverage: GYRE.O ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes